Coexistent bronchogenic carcinoma and active pulmonary tuberculosis.
Sixty-four cases of coexistent bronchogenic carcinoma and active pulmonary tuberculosis were diagnosed between 1969 and 1976. The majority were male chronic cigarette smokers in their fifth and sixth decades. Human bacilli were isolated in 48 patients (88.9 percent) and atypical bacilli in six patients (11.1 percent). All of the atypical bacilli and 8.3 percent of the human bacilli were found to be resistant to the first line antituberculous drugs. All patients, except two who died following resection, were given a course of antituberculous drugs with 93.8 percent successful sputum conversion. Uncontrolled or disseminated tuberculous infection was not observed. Forty-five patients (70.3 percent) underwent pulmonary resection. Median survival time of those who had curative resection was 14.3 months with a 5 year survival rate of 13.2 percent. Median survival times of those treated by palliative resection plus anticancer chemotherapy and by anticancer chemotherapy alone were 8.3 months and 11.1 months, respectively. None of these patients survived more than 30 months. It appears that, clinically, each disease runs its own course with little effect on the other.
D000230:Adenocarcinoma / Q000150:complications; D000328:Adult; D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000150:complications* / Q000628:therapy; D018288:Carcinoma, Small Cell / Q000150:complications; D002294:Carcinoma, Squamous Cell / Q000150:complications; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009161:Mycobacterium / Q000302:isolation & purification; D011379:Prognosis; D014397:Tuberculosis, Pulmonary / Q000150:complications* / Q000382:microbiology / Q000628:therapy
D000995:Antitubercular Agents